Protein (1)
En ligne (1)
Human (1)
His Tag & Avi Tag (1)
Biotin-labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HLM-H82Eq | HEK293 | Biotinylated Human HLA-B*15:02&B2M Monomer Protein (Peptide free, MALS verified) |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| IPP-204106 | N6L; Nucant-6L; IPP-204106; IPP-204106N; poyplexed IPP-204106 | Phase 2 Clinical | Immupharma Plc | Solid tumours; Neoplasms | Details |
| AS-1411 | AGRO-100; GR-026-B; AS-1411; ACT-GRO-777 | Phase 2 Clinical | University Of Louisville, Antisoma, University Of Alabama At Birmingham | Solid tumours; Neoplasms | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Tsinghua University, Beijing Protgen Biotechnology Development Co Ltd, Beijing Proji Pharmaceutical Technology Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| APTA-16 | APTA-16; SJP1604 | Phase 1 Clinical | Aptabio Therapeutics Inc | Liver Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Simcere Bio-Pharmaceutical Co Ltd | 2005-09-12 | Head and Neck Neoplasms; Esophageal Neoplasms; Ascites; Osteosarcoma; Nasopharyngeal Carcinoma; Brain metastases; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung | Details |




